alexa Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
Oncology

Oncology

Journal of Carcinogenesis & Mutagenesis

Author(s): Ross JS

Abstract Share this page

Abstract The HER2 (ERBB2) oncogene encodes a transmembrane tyrosine kinase receptor that has evolved as a major biomarker of invasive breast cancer and target of therapy for the disease. HER2 gene amplification or protein overexpression is encountered in approximately 20\% of newly diagnosed breast cancers and is a validated adverse prognostic factor with a mean relative risk for overall survival of 2.74. A series of quality assurance recommendations for the marketed slide-based HER2 testing approaches including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH/SISH) has recently been published by the American Society of Clini- cal Oncology - College of American Pathologists (ASCO-CAP). Testing issues, such as the impact of chromosome 17 polysomy and local versus central HER2 testing and emerging novel HER2 testing techniques, including messenger RNA (mRNA)-based testing by real time polymerase chain reaction (RT-PCR) and DNA microarray methods, HER2 receptor dimerization, phosphorylated HER2 receptors and HER2 status in circulating tumor cells are of current interest in the management of breast cancer. Also of significant interest are the evolving lists of biomarkers proposed to predict resistance to the major anti-HER2 therapies, trastuzumab and lapatinib. Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved. This article was published in Drug News Perspect and referenced in Journal of Carcinogenesis & Mutagenesis

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]ine.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords